Hansoh Pharma grants Roche exclusive license for ADC

17 October 2025

Shares of China’s Hansoh Pharmaceutical (HK: 03692) edged up 2% to HK$36.50 as it announced a license agreement with Roche (ROG: SIX) for HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor (TOPOi) payload.

Hansoh Pharma granted the Swiss pharma giant an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to progress the clinical development and commercialization of HS-20110.

This is the latest move by Roche in expanding its ADC portfolio, which includes a deal with China’s Innovent Biologics (HKEX: 01801), a deal similarly focused on bulking up its ADC pipeline in early 2024, paying $50 million upfront to collaborate with MediLink Therapeutics and with UK biotech Oxford BioTherapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK